Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Sandostatin LAR once-monthly depot formulation

Dec. 7, 1998

Phase II clinical trial demonstrates ALX1-11 effective in treating osteoporosis

Dec. 7, 1998

SB files for E.U. approval of Avandia for treatment of type II diabetes

Dec. 4, 1998

Shionogi reports synthesis and initial pharmacological testing of new NPY antagonists

Dec. 4, 1998

New SERMS from Lilly

Dec. 4, 1998

Dyax and Genzyme General to develop new antiinflammatory treatment

Dec. 3, 1998

Another market introduction for Lilly's SERM for postmenopausal women

Dec. 1, 1998

One Alkermes-R.W. Johnson collaboration makes progress, while another is terminated

Dec. 1, 1998

SB submits novel type II diabetes Rx for FDA approval

Dec. 1, 1998

FDA completes review of BioTime's NDA for Hextend

Dec. 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...